Skip to main content
. 2018 Dec 4;2018(12):CD011901. doi: 10.1002/14651858.CD011901.pub2

Stanganelli 2000.

Study characteristics
Patient sampling Study design: Case series
Data collection: Retrospective
Period of data collection 1994 ‐ 1996
Country Italy
Patient characteristics and setting Inclusion criteria: Patients with pigmented skin lesions referred by dermatologists and general practitioners either for pre‐surgical assessment or consultation
Setting: Specialist unit (skin cancer/pigmented lesions clinic)
Prior testing: Patients referred for pre‐surgical assessment or consultation indicating they have had prior tests
Setting for prior testing: Primary: some patients referred for consultation only; dermoscopy findings are reported back and management decision remains with referring clinician; Secondary (general dermatology)
Exclusion criteria: NR
Sample size (patients): N eligible: 1556
Sample size (lesions): N eligible: 3372; N included: 3372
Participant characteristics: Median age 30 years, range 10 to 94; Male: 522 (34%)
Lesion characteristics: NR
Index tests Visual inspection (VI) ABCD
Method of diagnosis: In‐person diagnosis
Prior test data: N/A in‐person diagnosis
Other test data: Dermoscopic and clinical images subsequently presented separately to observer subsequent to diagnosis using clinical images alone
Diagnostic threshold: NR
Diagnosis based on: Single observer; N = 1
Observer qualifications: NR; described as 1 of the co‐authors and study based in skin cancer clinic ‐ likely dermatologist
Experience in practice: Not described
Experience with dermoscopy: Not described
Other detail: A crude clinical image (magn x 6 and x 10) was recorded in the digital database
Dermoscopy: Pattern analysis
 Method of diagnosis: Unclear; participants seen in person but dermoscopic diagnosis made based on digital ELM image (by same clinician as in‐person clinical dx)
Prior test data: Combined clinical/dermoscopy diagnosis
Diagnostic threshold: Diagnosis described as based on an integrated synopsis of the patterns most commonly described in the literature (Steiner 1993) and generally associated with known histologic counterparts. Features were assessed described in detail with multiple references, including: presence of pigment network, sharp margins, abrupt edge of pigment network, branched streaks, pseudopods, radial streaming, brown globules, pigment dots, whitish or whitish‐blue veil, grey‐blue areas, white or depigmented areas, maple leaf areas, milia‐cysts, horny plugs and vascular patterns.
Test observers: As described for Visual Inspection (above)
Experience with dermoscopy:
Any other detail. The equipment consisted of a Leica Wild M‐650 stereomicroscope (Leica AG, Heerbrugg, Switzerland), a Sony 3ccd DXC‐930P colour video camera, an AT‐Vista videographics adapter, and IBM personal computer, a Sony Trinitron Analog PVM‐2043MD monitor, and the DBDERMO MIPS software
Target condition and reference standard(s) Reference standard: Histological diagnosis plus follow‐up; histology report of known surgical excisions (n = 262) plus a cancer registry‐based follow‐up of benign cases (N = 3110)
Target condition (Final diagnoses): Melanoma (in situ and invasive, or not reported): 55; BCC: 43;
'Benign' diagnoses: 3274
Flow and timing Excluded participants: None reported
Time interval to reference test: NR
Comparative Time interval between index test(s): not clearly reported just indicated that D‐ELM was performed soon after clinical examination
Notes
Methodological quality
Item Authors' judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random sample of patients enrolled? Yes    
Was a case‐control design avoided? Yes    
Did the study avoid inappropriate exclusions? Yes    
Are the included patients and chosen study setting appropriate? Yes    
Did the study avoid including participants with multiple lesions? No    
    Low High
DOMAIN 2: Index Test Visual Inspection (in‐person)
Were the index test results interpreted without knowledge of the results of the reference standard? Yes    
If a threshold was used, was it pre‐specified? Yes    
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?      
Was the test applied and interpreted in a clinically applicable manner? Yes    
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes    
Was the test interpretation carried out by an experienced examiner? Unclear    
    Low Unclear
DOMAIN 2: Index Test Dermoscopy (in‐person)
Were the index test results interpreted without knowledge of the results of the reference standard? Yes    
If a threshold was used, was it pre‐specified? Yes    
For studies reporting the accuracy of multiple diagnostic thresholds, was each threshold or algorithm interpreted without knowledge of the results of the others?      
Was the test applied and interpreted in a clinically applicable manner? Unclear    
Were thresholds or criteria for diagnosis reported in sufficient detail to allow replication? Yes    
Was the test interpretation carried out by an experienced examiner? Unclear    
    Low Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely to correctly classify the target condition? No    
Were the reference standard results interpreted without knowledge of the results of the index tests? Unclear    
Expert opinion (with no histological confirmation) was not used as a reference standard Yes    
Was histology interpretation carried out by an experienced histopathologist or by a dermatopathologist? Unclear    
Were the reference standard results interpreted without knowledge of the referral diagnosis? Unclear    
    High Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate interval between index test and reference standard? Unclear    
Did all patients receive the same reference standard? No    
Were all patients included in the analysis? Yes    
If the reference standard includes clinical follow‐up of borderline/benign appearing lesions, was there a minimum follow‐up following application of index test(s) of at least: 3 months for melanoma or cSCC or 6 months for BCC? Yes    
If more than one algorithm was evaluated for the same test, was the interval between application of the different algorithms 1 month or less?      
    High